Top Five Articles on 360Dx Last Week: Outlook for COVID-Testing Firms; FDA LDT Regulation; and More
Last week, readers were most interested in a story exploring the outlook for firms that have focused almost solely on COVID-19 testing.
Abbott Gains FDA Clearance for Lab-Based TBI Test
The assay will run on Abbott's Alinity I instrument and is intended to help evaluate patients with mild concussions.
Tesis Biosciences to Develop miRNA Biomarkers for mTBI Diagnosis
On the heels of its Genome Explorations acquisition, the company wants to create a biomarker panel to differentiate mild traumatic brain injury from PTSD.
Abbott Test Can Be Used to Predict Death, Disability for Patients With TBI, Study Finds
The researchers studied the value of testing patients with traumatic brain injury for the GFAP and UCH-L1 markers using Abbott Labs' point-of-care i-STAT Alinity System.
The firm said it believes that the results of a recent study are representative of the broader utility of the test and its potential for broad application to diagnose concussions.